Emavusertib

BIOLOGICAL9 trials

Sponsors

Curis, Inc., National Cancer Institute (NCI), Washington University School of Medicine

Conditions

Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia, Myelodysplasia-RelatedB-cell MalignanciesChronic Lymphocytic LeukemiaMetastatic Biliary Tract Cancer

Phase 1

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

RecruitingNCT03328078

Curis, Inc.Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy +1

Start: 2017-12-28End: 2026-10-31Target: 152Updated: 2025-06-05

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

SuspendedNCT04278768

Curis, Inc.Acute Myelogenous Leukemia, Myelodysplastic Syndrome

Start: 2020-07-06End: 2026-04-01Target: 366Updated: 2026-03-19

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

RecruitingNCT05685602

National Cancer Institute (NCI)Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 +1

Start: 2023-06-12End: 2026-04-30Target: 43Updated: 2026-04-03

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

RecruitingNCT06439836

National Cancer Institute (NCI)Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma

Start: 2025-05-05End: 2027-06-01Target: 27Updated: 2026-04-03

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

RecruitingNCT06696768

National Cancer Institute (NCI)Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8 +1

Start: 2025-06-23End: 2026-12-31Target: 24Updated: 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

RecruitingNCT07107750

Washington University School of MedicineMetastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma

Start: 2026-03-27End: 2032-05-31Target: 48Updated: 2026-04-03

Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecruitingNCT05564390

National Cancer Institute (NCI)Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Myelodysplasia-Related +2

Start: 2024-06-18End: 2029-05-15Target: 2000Updated: 2026-04-03

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

RecruitingNCT07271667

Curis, Inc.B-cell Malignancies, Chronic Lymphocytic Leukemia

Start: 2026-02-01End: 2027-11-01Target: 108Updated: 2026-03-30

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)

Not yet recruitingNCT07463820

National Cancer Institute (NCI)Myelodysplastic Syndrome

Start: 2026-06-19End: 2027-12-31Target: 270Updated: 2026-04-03

Related Papers

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Blood2025-11-03

CTNI-59. ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION

Neuro-Oncology2025-11-01

CTNI-63. PRELIMINARY SAFETY AND EFFICACY OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS

Neuro-Oncology2025-11-01

Abstract A069: A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC)

Cancer Research2025-09-28

Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.

Journal of Clinical Oncology2025-05-28

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Blood2024-11-055 citations

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Blood2024-11-053 citations

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor

Blood2024-11-052 citations

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood2024-11-051 citations

Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.

Journal of Clinical Oncology2024-06-012 citations

Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).

Journal of Clinical Oncology2024-06-012 citations

Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).

Journal of Clinical Oncology2024-06-011 citations

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with <i>FLT3</i> Mutation

Blood2023-11-025 citations

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Blood2023-11-023 citations

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

Blood2023-11-02

688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib

Regular and Young Investigator Award Abstracts2023-10-31

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.

2023-03-0120 citations

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Blood2022-11-152 citations

CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL

Neuro-Oncology2022-11-011 citations

Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

Journal of Clinical Oncology2022-06-0140 citations

11 more papers not shown